Today, we had a Zoom meeting with the Chairman, President and CEO of an immuno-oncology company in which he spoke freely about the endeavors his company is embarking on in the race to cure certain kinds of cancer. After our in-person meeting with him yesterday, we were intrigued to learn more about the company’s phase one clinical data of one of their lead projects, indicated for the treatment of positive leukemias such as acute myeloid leukemia (AML). We think you’ll find the talk interesting.

Log in below with your Premium Account to view the meeting, or check us out with a free trial.